Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Open Biopsy in Patients With Acute Progressive Neurologic Decline and Absence of Mass Lesion
Neurol 75:419-424, Schuette,A.J., et al, 2010
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
Unruptured Intracranial Aneurysms: Natural History, Clinical Outcome, and Risks of Surgical and Endovascular Treatment
Lancet 362:103-110,90, International Study of Unruptured Intracranial Ane, 2003
The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Genseng, Echinacea, Saw Palmetto, and Kava
Ann Int Med 136:42-53, Ernst,E., 2002
Role of Brain Biopsy in the Management of Focal Brain Lesions in HIV-Infected Patients
Neurol 54:993-997, Antinori,A.,et al, 2000
Risk Analysis of Treatment of Unruptured Aneurysms
JNNP 68:577-580, Mitchell,P.&Jakubowski,J., 2000
Functional Outcome and Quality of Life After Angiography and Operation for Unruptured Intracranial Aneurysms
JNNP 68:571-576, Raaymakers,T.W.M., 2000
Risks and Benefits of Screening for Intracranial Aneurysms in First-Degree Relatives of Patients with Sporadic Subarachnoid Hemorrhage
NEJM 341:1344-1350, The Magnetic Resonance Angiography in Relatives of, 1999